Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101 and Appoints Keith Orford, MD, PhD, as Chief Medical Officer

Ysios Capital

23.04.2025

SparingVision Receives FDA support– Ysios Capital

SparingVision Receives FDA Support to Initiate Phase II trial of SPVN06 in Geographic Atrophy Secondary to Dry-AMD

Ysios Capital

26.04.2025

CorWave successfully completes 6-Month Chronic In Vivo Study – Ysios Capital

CorWave Announces Successful Completion of 6-Month Chronic In Vivo Study, Paving the Way for Clinical Trial Initiation

home›Ysios Capital

Ysios Capital

Startups

Anaconda Biomed Announces Publication of ANAIS Study – Ysios Capital

Tagworks Pharmaceuticals Announces FDA IND Clearance – Ysios Capital

SparingVision Receives FDA support– Ysios Capital

CorWave successfully completes 6-Month Chronic In Vivo Study – Ysios Capital

home
›
Ysios Capital